Sign in Register

Helixate Fs (antihemophilic factor (FVIII) recombinant,full length)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Antihemophilic factor (recombinant) is a biosynthetic (recombinant DNA origin) preparation of antihemophilic factor (blood coagulation factor VIII). The drug is structurally similar to endogenous human factor VIII and produces the same biologic effects as plasma-derived antihemophilic factor (human).

USES: This medication is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding. People with low factor VIII levels are at risk for bleeding longer after an injury/surgery and for bleeding inside the body (especially into the joints and muscles).

This product contains a man-made form of factor VIII, also called antihemophilic factor. This product is used to temporarily replace the missing factor VIII, a protein (clotting factor) that is normally in the blood, so that the blood can clot and the bleeding can stop. This medication should not be used to treat von Willebrand disease.

Generic name: antihemophilic factor (FVIII) recombinant,full length
Pronunciation: (AN-tye-HEE-moe-FIL-ik FAK-tor, ree-KOM-bi-nant)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Helixate Fs

Intelligence content is not available yet.

Indications

The following indications are listed for Helixate Fs:

  • Bleeding Episode In Hemophilia A
  • Bleeding Prevention In Hereditary Factor Viii Deficiency
  • Hemophilia A

Also known as: Bleeding Prevention In Classic Hemophilia, Bleeding Prevention In Congenital Factor Viii Deficiency, Bleeding Prevention In Hemophilia A, Bleeding Prophylaxis In Hemophilia A, Congenital Factor Viii Deficiency Disease, Hemorrhage Prophylaxis In Hemophilia A, Hemorrhaging In Hemophilia A, Prevention Of Bleeding Episode In Hemophilia A.

Dosing

Dosage of antihemophilic factor (recombinant) is expressed in terms of international units (IU, units) of antihemophilic factor activity; 1 unit is approximately equal to the quantity of antihemophilic factor present in 1 mL of fresh pooled human plasma. In general, administration of 1 unit/kg of antihemophilic factor (recombinant) will increase the circulating factor VIII level by approximately 2 units/dL (2%).

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a 5-digit ZIP code. Searching does not change your profile.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data